Evidence map›Paper›PMID 42608480›Full record

ArticleThe EMBO journal2026

Canonical and non-canonical miRNA degradation shapes state transitions and stemness in breast cancer.

Carmela Rubolino, Manfredi D'Onghia, Chiara Tordonato, Arianna Sabò, Alessandro D'Agnelli, Sara Bisi, Roberto Giambruno, Bianca Giuliani, Matteo Jacopo Marzi, Francesco Nicassio

Abstract read
PubMed Publisher
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carmela RubolinoCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.
Manfredi D'OnghiaCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.
Chiara TordonatoDepartment of Experimental Oncology, European Institute of Oncology (IEO) - IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0001-6556-1747
Arianna SabòDepartment of Experimental Oncology, European Institute of Oncology (IEO) - IRCCS, Milan, Italy.
Alessandro D'AgnelliCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.ORCID http://orcid.org/0009-0004-6434-3237
Sara BisiCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.
Roberto GiambrunoCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.ORCID http://orcid.org/0000-0002-4566-261X
Bianca GiulianiCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy.ORCID http://orcid.org/0000-0001-7505-9697
Matteo Jacopo Marzi *Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy. matteo.marzi@iit.it.ORCID http://orcid.org/0000-0002-5068-782X
Francesco Nicassio *Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia (IIT) - Via Adamello 16, 20139, Milan, Italy. francesco.nicassio@iit.it.ORCID http://orcid.org/0000-0002-5954-5318

Funding

EC | H2020 | PRIORITY 'Excellent science' | H2020 Marie Skłodowska-Curie Actions (MSCA) 101072892EC | H2020 | PRIORITY 'Excellent science' | H2020 Marie Skłodowska-Curie Actions (MSCA) 101226670EC | NextGenerationEU (NGEU) Mission 4,Component 2,CUP B93D21010860004Fondazione AIRC per la ricerca sul cancro ETS (AIRC) 22438Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG22851Fondazione AIRC per la ricerca sul cancro ETS (AIRC) IG32172Fondazione Cariplo (Cariplo Foundation) 2015-0590Fondazione Cariplo (Cariplo Foundation) 2016-0615
6 · The paper itself

Abstract

Target-directed microRNA degradation (TDMD) is an emerging post-transcriptional mechanism that controls miRNA turnover, yet its role in human cancers remains largely unexplored. Here, we combine CRISPRi-mediated ZSWIM8 depletion, miRNA-seq, and AGO2-eCLIP to define the TDMD landscape across breast cancer subtypes. We identify 19 high-confidence TDMD substrates, including miR-29b-3p and miR-33a/b-5p, and show that TDMD shapes miRNA target occupancy and target repression. Integration with single-cell transcriptomics reveals that TDMD of miR-29b-3p triggered by NREP transcript is associated with transcriptional plasticity along the epithelial-mesenchymal axis and marks a stem-like subpopulation of malignat cells with tumor-initiating potential in triple-negative breast cancer. Unexpectedly, we also uncover a non-canonical TDMD mechanism, independent of ubiquitin ligase ZSWIM8 and the proteasome, which includes SERPINE1-triggered miR-30c-5p degradation, conferring paclitaxel resistance and enhancing sphere-forming potential. These findings establish target-directed microRNA degradation as a functional layer of miRNA regulation in cancer, linking miRNA decay to cellular state transitions and therapeutic response. Our results broaden the mechanistic spectrum of TDMD and provide a framework to investigate how regulated miRNA decay contributes to aggressive breast cancer phenotypes.

Indexed as

Breast NeoplasmsMicroRNAsNeoplastic Stem CellsRNA StabilityAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMicroRNAs

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.